· 1 min read
Peter Gough, NSF’s Executive Director of Pharma Biotech, provided a practical overview of the regulatory implications of Brexit at the 2018 Pharmaceutical Industry Network Group (PING) seminar, held June 8, 2018 in Hertfordshire, UK.
According to Gough, with the official Brexit date less than a year away, it is imperative for pharmaceutical manufacturers to prepare for impending Brexit negotiations and future economic relationships.
In his presentation, Gough stated that shortages could arise if extra administrative or customs procedures are introduced. He also emphasized the importance of other factors, such as the European Medicines Agency (EMA)'s relocation to Amsterdam, the role of the Medicines and Healthcare products Regulatory Agency (MHRA), centralized marketing authorizations and safety features around data.
“If we are to avoid issues with the supply of medicines, we need sensible, pragmatic decisions from both UK and EU politicians. The time to act is now,” said Gough. “Sitting on the fence is no longer an option."
Learn more about all the presenters at this round-up of the 2018 PING seminar.
Join NSF at RAPS Convergence 2023
August 2023 Pharma News Update
July 2023 Pharma News Update